Spinal Central Effects of Peripherally Applied Botulinum Neurotoxin A in Comparison between Its Subtypes A1 and A2.
Spinal Central Effects of Peripherally Applied Botulinum Neurotoxin A in Comparison between Its Subtypes A1 and A2.
复制标题
DOI：
10.3389/fneur.2014.00098
复制
发表时间：
2014
影响因子：
3.4
通讯作者：
Kaji R
中科院分区：
文献类型：
--
作者：
Koizumi H;Goto S;Okita S;Morigaki R;Akaike N;Torii Y;Harakawa T;Ginnaga A;Kaji R
Because of its unique ability to exert long-lasting synaptic transmission blockade, botulinum neurotoxin A (BoNT/A) is used to treat a wide variety of disorders involving peripheral nerve terminal hyperexcitability. However, it has been a matter of debate whether this toxin has central or peripheral sites of action. We employed a rat model in which BoNT/A1 or BoNT/A2 was unilaterally injected into the gastrocnemius muscle. On time-course measurements of compound muscle action potential (CMAP) amplitudes after injection of BoNT/A1 or BoNT/A2 at doses ranging from 1.7 to 13.6 U, CMAP amplitude for the ipsilateral hind leg was markedly decreased on the first day, and this muscle flaccidity persisted up to the 14th day. Of note, both BoNT/A1 and BoNT/A2 administrations also resulted in decreased CMAP amplitudes for the contralateral leg in a dose-dependent manner ranging from 1.7 to 13.6 U, and this muscle flaccidity increased until the fourth day and then slowly recovered. Immunohistochemical results revealed that BoNT/A-cleaved synaptosomal-associated protein of 25 kDa (SNAP-25) appeared in the bilateral ventral and dorsal horns 4 days after injection of BoNT/A1 (10 U) or BoNT/A2 (10 U), although there seemed to be a wider spread of BoNT/A-cleaved SNAP-25 associated with BoNT/A1 than BoNT/A2 in the contralateral spinal cord. This suggests that the catalytically active BoNT/A1 and BoNT/A2 were axonally transported via peripheral motor and sensory nerves to the spinal cord, where they spread through a transcytosis (cell-to-cell trafficking) mechanism. Our results provide evidence for the central effects of intramuscularly administered BoNT/A1 and BoNT/A2 in the spinal cord, and a new insight into the clinical effects of peripheral BoNT/A applications.
登录
查看更多内容
影响因子：
3.7
作者：
Filipović B;Matak I;Bach-Rojecky L;Lacković Z
通讯作者：
Lacković Z
影响因子：
5.3
作者：
Koizumi H;Morigaki R;Okita S;Nagahiro S;Kaji R;Nakagawa M;Goto S
通讯作者：
Goto S
影响因子：
5
作者：
Bach-Rojecky, Lidija;Salkovic-Petrisic, Melita;Lackovic, Zdravko
通讯作者：
Lackovic, Zdravko
影响因子：
4.2
作者：
Matak, Ivica;Riederer, Peter;Lackovic, Zdravko
通讯作者：
Lackovic, Zdravko
影响因子：
9.9
作者：
MorenoLopez, B;Pastor, AM;DelgadoGarcia, JM
通讯作者：
DelgadoGarcia, JM